The FDA granted Dyne Therapeutics orphan status for its treatment of Duchenne muscular dystrophy. Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DYN:
- Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
- Dyne Therapeutics to Present at Upcoming Investor Conferences
- Dyne Therapeutics price target raised to $20 from $17 at Chardan
- Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Dyne Therapeutics expects cash to fund operations through 2024